Survival analysis for older patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after progression of first-line gefitinib.

Abstract excerpt

AIM: Currently, little studies focus on treatment strategies and survival after progression of gefitinib in older patients with epidermal growth factor receptor )EGFR( mutant advanced non-small-cell lung cancer (NSCLC). The aim of this study was to investigate the influence of different treatment modalities on survival after progression of gefitinib in older patients. METHODS: This is a retrospective analysis...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Age Factors
• Share to Carcinoma, Non-Small-Cell Lung